One Pharmaceutical Company Says It Already Has 'Vaccine' in Testing for Omicron Variant

Plus: Government report reveals how we already know that vaccines transmit the Omicron variant.

Pfizer-BioNTech, fresh off sky-high profits off of its government-mandated 'vaccines,' is already mullying a 'future relaunch' of a Covid-19 vaccine to deal with the Omicron variant. It looks like a lesser-known pharmaceutical company, Novavax, however, may beat it to the punch.

Novavax said on Friday it has "started working on a version of its COVID-19 vaccine to target the variant detected in South Africa" and "would have the shot ready for testing and manufacturing in the next few weeks," Reuters reported.

"The company's COVID-19 shot contains an actual version of the virus' spike protein that cannot cause disease but can trigger the immune system," Reuters noted. "The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529."

"The initial work will take a few weeks," a company spokesperson said. "Shares of the company closed up nearly 9% on Friday."

The report notes that Novavax's vaccine received its first emergency use approval earlier this month in Indonesia, followed by the Philippines.

"The company has said it is on track to file for U.S. approval by the end of the year," the report continued. "It has also filed for approvals with the European Medicines Agency as well as in Canada."

The Omicron variant (the WHO just wouldn’t allow their boss Xi have a variant named after him and so skipped two Greek alphabet letters) is believed to have originated in Botswana, and may be playing a role in a Covid surge in South Africa. The variant has been identified in Botswana, South Africa, the U.K., Hong Kong, and Amsterdam in The Netherlands, thus far.

While the U.S. news media pretend to now know if the ‘fully vaccinated’ transmit the Omicron variant, there is an easy way that we can already rule out the vaccines stopping the spread of B.1.1.529.